Posted by Michael Wonder on 28 Jul 2022
Drug industry poised for rare political loss on prices
28 July 2022 - Senate deal giving Medicare limited authority to negotiate prices would chip at power of Big Pharma.
Year after year for most of two decades, proposals to allow the government to negotiate lower prices from drug companies for Medicare recipients have wound up dead in Congress, defeated by the powerful pharmaceutical industry and its allies. Now the Washington drug lobby is on the cusp of a rare political loss.
